Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

36.16
-0.2500-0.69%
Post-market: 36.440.2800+0.77%19:30 EDT
Volume:2.27M
Turnover:81.23M
Market Cap:3.49B
PE:-7.68
High:36.41
Open:36.13
Low:35.06
Close:36.41
52wk High:72.66
52wk Low:35.06
Shares:96.64M
Float Shares:95.45M
Volume Ratio:0.94
T/O Rate:2.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7061
EPS(LYR):-4.3646
ROE:-43.62%
ROA:-28.02%
PB:2.81
PE(LYR):-8.28

Loading ...

Xenon Pharmaceuticals - Enrollment in X-Nova2 Study in Mdd Completed; Topline Data Expected Q1 2027

THOMSON REUTERS
·
Sep 18

Xenon Pharmaceuticals Inc: Voluntary Action Does not Impact Ongoing Epilepsy Studies

THOMSON REUTERS
·
Sep 18

Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.

Dow Jones
·
Sep 11

Wells Fargo Sticks to Its Buy Rating for Xenon (XENE)

TIPRANKS
·
Sep 02

Xenon CMO Christopher John Kenney Reports Disposal of Common Shares Worth $425,469.33

Reuters
·
Sep 01

Xenon Grants 13,450 Inducement Stock Options, 7,850 RSUs to New Hires at $61.93 Strike

Reuters
·
Aug 29

Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 29

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 29

Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

Simply Wall St.
·
Aug 19

Xenon Pharmaceuticals Director Steven Gannon Disposes of 10,000 Common Shares for $640,550

Reuters
·
Aug 14

J.P. Morgan Remains a Buy on Xenon (XENE)

TIPRANKS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)

TIPRANKS
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)

TIPRANKS
·
Aug 08

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

MT Newswires Live
·
Aug 08

Evercore ISI Reaffirms Their Buy Rating on Xenon (XENE)

TIPRANKS
·
Aug 08

Wedbush Adjusts PTon Xenon Pharmaceuticals to $71 From $63, Maintains Outperform Rating

MT Newswires Live
·
Aug 07

RBC Adjusts Xenon Pharmaceuticals PT to $81 From $82, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 07

Xenon Pharmaceuticals Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Earnings Flash (XENE) Xenon Posts Q2 Loss Per Share $1.11, vs. FactSet Est of $1.14 Loss

MT Newswires Live
·
Aug 07

Xenon Pharmaceuticals reports Q2 EPS ($1.11), consensus ($1.16)

TIPRANKS
·
Aug 07